Insider trades
Open-market buys and sales that US company officers, directors and 10% owners file, newest filing first.
| Trade type | ||||||||
|---|---|---|---|---|---|---|---|---|
Paul SchimmelDirector | aTYR PharmaATYR | Open-market buy | 05/27 | 05/28 | 100,000 sh | $0.50 | $50,000 | +14.7% |
aTYR PharmaATYR | Open-market sale | 02/04 | 02/04 | 1,558 sh | $0.98 | $1,526.84 | −4.0% | |
Nancy DenyesGeneral Counsel | aTYR PharmaATYR | Open-market sale | 02/04 | 02/04 | 1,118 sh | $0.98 | $1,095.64 | −3.3% |
Sanjay ShuklaPresident and CEO | aTYR PharmaATYR | Open-market sale | 02/04 | 02/04 | 3,745 sh | $0.98 | $3,670.1 | −2.4% |
aTYR PharmaATYR | Open-market buy | 25/10/08–25/10/09 | 25/10/09 | 1,000,000 sh2 trades | $0.91avg. | $912,719.96 | +242.1% | |
Jane A. GrossDirector | aTYR PharmaATYR | Open-market buy | 25/03/17 | 25/03/17 | 3,750 sh | $4.00 | $15,000 | +62.5% |
aTYR PharmaATYR | Open-market sale | 25/02/04 | 25/02/04 | 1,254 sh | $3.78 | $4,740.12 | −3.8% | |
Nancy DenyesGeneral Counsel | aTYR PharmaATYR | Open-market sale | 25/02/04 | 25/02/04 | 899 sh | $3.78 | $3,398.22 | −3.3% |
aTYR PharmaATYR | Open-market buy | 24/07/22–24/07/24 | 24/07/24 | 100,000 sh3 trades | $1.84avg. | $184,468.84 | +31.9% | |
Nancy DenyesGeneral Counsel | aTYR PharmaATYR | Open-market buy | 24/06/05 | 24/06/06 | 5,000 sh | $1.86 | $9,300 | +29.0% |